SGLT4like
SGLT4like is a class of drugs that act as agonists or partial agonists of the sodium-glucose cotransporter 4 (SGLT4) protein. SGLT4 is a transporter protein found in the kidneys that reabsorbs glucose from the filtrate back into the bloodstream, thereby regulating glucose levels. SGLT4like drugs work by inhibiting the reabsorption of glucose, leading to increased urinary excretion of glucose and a subsequent reduction in blood glucose levels. This mechanism makes SGLT4like drugs particularly useful in the treatment of type 2 diabetes mellitus, as they can lower both blood glucose levels and blood pressure.
The first SGLT4like drug to be approved was canagliflozin, which was approved by the U.S. Food and
In addition to their glucose-lowering effects, SGLT4like drugs have been shown to have other beneficial effects,
The exact mechanism by which SGLT4like drugs reduce the risk of cardiovascular events is not fully understood,
In summary, SGLT4like drugs are a class of medications that act on the SGLT4 protein to lower